The synergistic effects of this combination are attributed to the unique properties of its components: A) RDB 1462: Enhances the activation and proliferation of tumor-specific T cells; B) XRT: Controls primary tumor growth and triggers the release of tumor antigens that prime the immune system’s specificity towards secondary tumor sites; C) αPD1 therapy: Blocks the PD1/PD-L1 inhibitory pathway, unleashing T cell activity against tumor cells. This evidence concerns the gene CD274 and neoplasm.